Open Access

A germline alteration of ERBB2 increases the risk of breast cancer in Chinese Han women with a familial history of malignant tumors

  • Authors:
    • Yan Ju
    • Lifeng Wang
    • Shengjun Ta
    • Rui Shu
    • Shanling Yang
    • Xican Gao
    • Hongping Song
    • Liwen Liu
  • View Affiliations

  • Published online on: July 22, 2019     https://doi.org/10.3892/ol.2019.10646
  • Pages: 2885-2890
  • Copyright: © Ju et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Previous studies have demonstrated that a family history of breast cancer is considered a risk factor, and hereditary factors may be involved in breast cancer pathogenesis. Next‑generation sequencing techniques were used to analyze 111 cancer‑associated genes in patients with breast cancer with a familial history of malignant tumors in the pre‑experiment and a novel variant, receptor tyrosine‑protein kinase erbB‑2 (ERBB2) c.338G>A: p.R113Q was identified in two cases of breast cancer. ERBB2 is considered an important oncogene, and overexpression or mutation of the ERBB2 gene may lead to the occurrence or metastasis of tumors. To assess a potential association between rs185670819 and breast cancer, 117 patients with breast cancer and a familial history of any cancer, who were diagnosed by experienced pathologists at the Xijing Hospital (Shaanxi, China) between July 2015 and December 2016, were recruited. The presence of the missense variant was confirmed using bi‑directional Sanger sequencing of samples from the patients with breast cancer and 250 healthy controls. The effects of the missense mutation on the structure and function of ERBB2 were analyzed in silico. The missense variant, R113Q, in patients with breast cancer with a familial history of malignant tumors in China, was present in 8 patients [6.8% (95% CI: 3.21‑13.45)] and 3 of 250 healthy controls [1.2% (95% CI: 0.31‑3.76; OR=6.04, 95% CI: 1.573‑23.214, P=0.009)]. Of the 8 patients with the R113Q variant, 6 patients had a family history of cancer of the digestive system. The present study suggests that ERBB2 c.338G>A: p.R113Q may be a potential risk factor in the development and progression of breast cancer.

Related Articles

Journal Cover

September 2019
Volume 18 Issue 3

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Ju, Y., Wang, L., Ta, S., Shu, R., Yang, S., Gao, X. ... Liu, L. (2019). A germline alteration of ERBB2 increases the risk of breast cancer in Chinese Han women with a familial history of malignant tumors. Oncology Letters, 18, 2885-2890. https://doi.org/10.3892/ol.2019.10646
MLA
Ju, Y., Wang, L., Ta, S., Shu, R., Yang, S., Gao, X., Song, H., Liu, L."A germline alteration of ERBB2 increases the risk of breast cancer in Chinese Han women with a familial history of malignant tumors". Oncology Letters 18.3 (2019): 2885-2890.
Chicago
Ju, Y., Wang, L., Ta, S., Shu, R., Yang, S., Gao, X., Song, H., Liu, L."A germline alteration of ERBB2 increases the risk of breast cancer in Chinese Han women with a familial history of malignant tumors". Oncology Letters 18, no. 3 (2019): 2885-2890. https://doi.org/10.3892/ol.2019.10646